- Home
- CNXC vs PTGX Comparison
CNXC vs PTGX Comparison
Compare CNXC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNXC
- PTGX
- Stock Information
- Founded
- CNXC 1991
- PTGX 2006
- Country
- CNXC United States
- PTGX United States
- Employees
- CNXC N/A
- PTGX N/A
- Industry
- CNXC Computer Software: Prepackaged Software
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CNXC Technology
- PTGX Health Care
- Exchange
- CNXC Nasdaq
- PTGX Nasdaq
- Market Cap
- CNXC 2.8B
- PTGX 2.8B
- IPO Year
- CNXC N/A
- PTGX 2016
- Fundamental
- Price
- CNXC $39.56
- PTGX $41.65
- Analyst Decision
- CNXC Buy
- PTGX Strong Buy
- Analyst Count
- CNXC 5
- PTGX 7
- Target Price
- CNXC $79.00
- PTGX $53.57
- AVG Volume (30 Days)
- CNXC 619.9K
- PTGX 700.6K
- Earning Date
- CNXC 09-25-2024
- PTGX 11-07-2024
- Dividend Yield
- CNXC 3.35%
- PTGX N/A
- EPS Growth
- CNXC N/A
- PTGX N/A
- EPS
- CNXC 3.08
- PTGX 2.68
- Revenue
- CNXC $9,401,638,000.00
- PTGX $323,795,000.00
- Revenue This Year
- CNXC $37.81
- PTGX $396.93
- Revenue Next Year
- CNXC $2.26
- PTGX N/A
- P/E Ratio
- CNXC $12.85
- PTGX $15.15
- Revenue Growth
- CNXC 44.09
- PTGX 125.73
- 52 Week Low
- CNXC $36.28
- PTGX $16.80
- 52 Week High
- CNXC $106.10
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- CNXC 35.80
- PTGX 41.01
- Support Level
- CNXC $36.28
- PTGX $33.31
- Resistance Level
- CNXC $44.21
- PTGX $48.86
- Average True Range (ATR)
- CNXC 1.64
- PTGX 2.82
- MACD
- CNXC 0.26
- PTGX -0.62
- Stochastic Oscillator
- CNXC 41.39
- PTGX 53.63
About CNXC Concentrix Corporation
Concentrix Corp is a technology-enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five primary industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Canada, Germany, Great Britain and others.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.